High Tech (Korea) Performance
| 106190 Stock | KRW 14,090 60.00 0.42% |
The company retains a Market Volatility (i.e., Beta) of 0.12, which attests to not very significant fluctuations relative to the market. As returns on the market increase, High Tech's returns are expected to increase less than the market. However, during the bear market, the loss of holding High Tech is expected to be smaller as well. At this point, High Tech Pharm has a negative expected return of -0.1%. Please make sure to check out High Tech's market risk adjusted performance, coefficient of variation, jensen alpha, as well as the relationship between the mean deviation and standard deviation , to decide if High Tech Pharm performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days High Tech Pharm has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
| Total Cashflows From Investing Activities | -1.3 B |
High |
High Tech Relative Risk vs. Return Landscape
If you would invest 1,524,000 in High Tech Pharm on August 31, 2024 and sell it today you would lose (115,000) from holding High Tech Pharm or give up 7.55% of portfolio value over 90 days. High Tech Pharm is generating negative expected returns and assumes 2.5139% volatility on return distribution over the 90 days horizon. Simply put, 22% of stocks are less volatile than High, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
High Tech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for High Tech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as High Tech Pharm, and traders can use it to determine the average amount a High Tech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0413
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 106190 |
Estimated Market Risk
| 2.51 actual daily | 22 78% of assets are more volatile |
Expected Return
| -0.1 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average High Tech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of High Tech by adding High Tech to a well-diversified portfolio.
High Tech Fundamentals Growth
High Stock prices reflect investors' perceptions of the future prospects and financial health of High Tech, and High Tech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on High Stock performance.
| Return On Equity | 0.0057 | |||
| Return On Asset | 6.0E-4 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | 0 % | |||
| Current Valuation | 137.37 B | |||
| Shares Outstanding | 7.09 M | |||
| Price To Earning | 17.75 X | |||
| Price To Sales | 0.83 X | |||
| Revenue | 73.29 B | |||
| EBITDA | 5.68 B | |||
| Cash And Equivalents | 11.27 B | |||
| Total Debt | 5.98 B | |||
| Debt To Equity | 0.01 % | |||
| Cash Flow From Operations | 6.93 B | |||
| Total Asset | 122.94 B | |||
| Retained Earnings | 68.32 B | |||
| Current Asset | 53.62 B | |||
| Current Liabilities | 12.76 B | |||
About High Tech Performance
By analyzing High Tech's fundamental ratios, stakeholders can gain valuable insights into High Tech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if High Tech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if High Tech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
High Tech Pharm Co., Ltd. develops, manufactures, sells, and distributes antibiotic pharmaceutical ingredients for injections for hospitals and doctors.Things to note about High Tech Pharm performance evaluation
Checking the ongoing alerts about High Tech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for High Tech Pharm help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| High Tech Pharm generated a negative expected return over the last 90 days | |
| The company reported the revenue of 73.29 B. Net Loss for the year was (1.23 B) with profit before overhead, payroll, taxes, and interest of 1.31 B. | |
| About 45.0% of the company shares are owned by insiders or employees |
- Analyzing High Tech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether High Tech's stock is overvalued or undervalued compared to its peers.
- Examining High Tech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating High Tech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of High Tech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of High Tech's stock. These opinions can provide insight into High Tech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for High Stock analysis
When running High Tech's price analysis, check to measure High Tech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy High Tech is operating at the current time. Most of High Tech's value examination focuses on studying past and present price action to predict the probability of High Tech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move High Tech's price. Additionally, you may evaluate how the addition of High Tech to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |